Cystic fibrosis (CF) is a complex genetic disorder with pulmonary involvement. CF patients have normal lungs at birth; but recurrent and chronic bacterial respiratory infections lead to progressive respiratory compromise, long-term morbidity, and mortality in the patients (
1,
2). Several bacterial species can colonize the respiratory tract of CF patients. The testing of respiratory secretions from these patients is a suitable method for detecting colonization with opportunistic bacteria (
2).
Pseudomonas aeruginosa is the main respiratory pathogen although other Gram-negative bacteria such as
Burkholderia cepacia,
Stenotrophomonas maltophilia, and
Acinetobacter baumannii are also detected in the respiratory tract and play key roles in pulmonary pathology (
1-
3).
P. aeruginosa can persist for a long time as a chronic infection to impair lung function (
3,
4). This microorganism is acquired from the environment or through patient-to-patient transmission (
5). Rarely may
Acinetobacter spp. be found in the respiratory secretions of CF patients (
6). The genus
Burkholderia is an adaptable Gram-negative bacterium, with some species such as
Burkholderia cepacia causing life-threatening infections in CF patients. Infections caused by these bacteria can be difficult to treat because of their significant antibiotic resistance (
6,
7). Although the prevalence of colonization with
Burkholderia cepacia complex is relatively low in CF patients, it is important as some genomovars of this bacterium can reduce survival after lung transplantation (
8).
Stenotrophomonas maltophilia is another bacterial species that commonly colonizes the respiratory tract of CF patients. However, the effect of this opportunistic pathogen on the development of CF lung disease has not yet been completely specified (
9).
Rapid detection and identification of pathogenic microorganisms in CF patients not only help prevent the patient-to-patient transmission, but also expedite the prompt institution of appropriate treatment for infected patients. Late detection impedes the eradication of these pathogens and leads to chronic infection (
5). Culture-based methods are time-consuming in the detection of bacteria from the airways of CF patients and they usually give false positive and false negative results due to colonization and previous antibiotic use, respectively. This is while molecular techniques can detect causal bacteria rapidly (
10,
11). Polymerase chain reaction (PCR) assays targeting the 16srRNA gene can be used for the detection of lung infection bacteria in CF patients (
10,
12).